

Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021) (By Type - Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North America, Europe, APAC, Latin America, MEA; By Country - USA, Canada, UK, Germany, India, Brazil, South Africa)

<https://marketpublishers.com/r/G20D4DD6D6AEN.html>

Date: October 2016

Pages: 175

Price: US\$ 2,600.00 (Single User License)

ID: G20D4DD6D6AEN

Abstracts

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global anemia drugs market on the basis of Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia), By Region (North America, Europe, APAC, Latin America, MEA); By Country (USA, Canada, UK, Germany, India, Brazil, South Africa).

Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.

Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and

Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.

Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 – 2021F, on account of rising incidences of anemia globally.

North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.

According to Azoth Analytics research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa)

Scope of the Report

The report provides Segmentation and Pipeline Analysis by Anemia Type

Iron Deficiency Anemia

Chronic Kidney Disease related Anemia

Sickle Cell Anemia

Aplastic Anemia

The report provides coverage by Region

North America

Europe

Asia Pacific

Latin America

Middle East and Africa (MEA)

The report provides coverage by Country

USA

Canada

UK

Germany

India

Brazil

South Africa

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. STRATEGIC RECOMMENDATIONS

- 3.1. North America and Europe to Generate High Revenue
- 3.2. Opportunity in Rare Anemia
- 3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers

4. GLOBAL ANEMIA DRUGS MARKET: AN OVERVIEW

- 4.1. Product Overview
- 4.2. Global Anemia Drugs Market
 - 4.1.1. By Value (Historic 2011-15)
 - 4.1.2. By Value (Forecast 2016E-2021F)
- 4.3. Global Iron Deficiency Anemia Drugs Market
 - 4.2.1. By Value (Historic 2011-15)
 - 4.2.2. By Value (Forecast 2016E-2021F)
- 4.4. Global CKD Anemia Drugs Market
 - 4.4.1. By Value (Historic 2011-15)
 - 4.4.2. By Value (Forecast 2016E-2021F)
- 4.5. Global Sickle Cell Anemia Drugs Market
 - 4.5.1. By Value (Historic 2011-15)
 - 4.5.2. By Value (Forecast 2016E-2021F)
- 4.6. Global Aplastic Anemia Drugs Market
 - 4.6.1. By Value (Historic 2011-15)
 - 4.6.2. By Value (Forecast 2016E-2021F)
- 4.7. Anemia Drugs Pipeline Analysis
 - 4.7.1. Sickle Cell Anemia
 - 4.7.2. CKD Anemia
 - 4.7.3. Aplastic Anemia
 - 4.7.4. Iron Deficiency Anemia
 - 4.7.5. Myelodysplastic syndrome Anemia

5. NORTH AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS

5.1. North America Anemia Drugs Market

5.1.1. By Value (Historic 2011-15)

5.1.2. By Value (Forecast 2016E-2021F)

5.2. North America Anemia Drugs Market: Country Overview – US, Canada

6. EUROPE ANEMIA DRUGS MARKET: AN ANALYSIS

6.1. Europe Anemia Drugs Market

6.1.1. By Value (Historic 2011-15)

6.1.2. By Value (Forecast 2016E-2021F)

6.2. Europe Anemia Drugs Market: Country Overview – UK, Germany

7. APAC ANEMIA DRUGS MARKET: AN ANALYSIS

7.1. APAC Anemia Drugs Market

7.1.1. By Value (Historic 2011-15)

7.1.2. By Value (Forecast 2016E-2021F)

7.2. North America Anemia Drugs Market: Country Overview – India

8. LATIN AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS

8.1. Latin America Anemia Drugs Market

8.1.1. By Value (Historic 2011-15)

8.1.2. By Value (Forecast 2016E-2021F)

8.2. Latin America Anemia Drugs Market: Country Overview – Brazil

9. MEA ANEMIA DRUGS MARKET: AN ANALYSIS

9.1. MEA Anemia Drugs Market

9.1.1. By Value (Historic 2011-15)

9.1.2. By Value (Forecast 2016E-2021F)

9.2. MEA Anemia Drugs Market: Country Overview – South Africa

10. MARKET DYNAMICS

10.1. Trends

10.2. Drivers

10.3. Challenges

11. M&A AND LICENSING ROUTE TO THE ANEMIA DRUGS TREATMENT MARKET

12. SWOT ANALYSIS

13. PORTER FIVE FORCE MODEL

14. COMPANY PROFILING AND DRUG MARKET POTENTIAL

Sickle Cell Anaemia

14.1. Global Blood Therapeutics (GBT)

14.1.1. Company Overview

14.1.2. GBT-440 (Drug of Global Blood Therapeutics)

14.1.2.1 Market Potential

14.2. Bluebird bio

14.2.1. Company Overview

14.2.2. LentiGlobin BB305 (Drug of Bluebird bio)

14.2.2.1 Stage of development

14.2.2.2 Overview

14.2.2.3 Clinical Data

14.2.2.4 Market Potential

14.3. GlycoMimetics

14.3.1. Company Overview

14.3.2. Rivipansel (Drug of GlycoMimetics)

14.3.2.1 Stage of development

14.3.2.2 Overview

14.3.2.3 Clinical Data

14.3.2.4 Market Opportunity

14.4. Mast Therapeutics

14.4.1. Company Overview

14.4.2. Vepoloxamer (Drug of Mast Therapeutics)

14.4.2.1 Stage of development

14.4.2.2 Overview

14.4.2.3 Clinical Data

14.4.2.4 Market Potential

CKD Anemia

14.5. GlaxoSmithKline

14.5.1. Company Overview

14.5.2. Daprodustat (Drug of GlaxoSmithKline)

14.5.2.1 Stage of development

- 14.5.2.2 Overview
- 14.5.2.3 Clinical Data
- 14.6. Fibrogen
 - 14.6.1. Company Overview
 - 14.6.2. Roxadustat (Drug of Fibrogen)
 - 14.6.2.1 Stage of development
 - 14.6.2.2 Overview
 - 14.6.2.3 Clinical Data
- 14.7. Akebia therapeutics
 - 14.7.1. Company Overview
 - 14.7.2. Vadadustat (Product of Akebia therapeutics)
 - 14.7.2.1 Stage of development
 - 14.7.2.2 Overview
 - 14.7.2.3 Clinical Data
- 14.8. Bayer AG
 - 14.8.1. Company Overview
 - 14.8.2. Molidustat (Drug of Bayer)
 - 14.8.2.1 Stage of development
 - 14.8.2.2 Overview
 - 14.8.2.3 Clinical Data
- 14.9. Eli Lilly
 - 14.9.1. Company Overview
 - 14.9.2. BMP-6 Mab (Drug of Eli Lilly)
 - 14.9.2.1 Stage of development
 - 14.9.2.2 Overview
 - 14.9.2.3 Clinical Data
 - 14.9.3. Sotatercept (Drug of Eli Lilly)
 - 14.9.3.1 Stage of development
 - 14.9.3.2 Overview
 - 14.9.3.3 Clinical Data
- Aplastic Anemia
- 14.10. Regen biopharma
 - 14.10.1. Hemaxellerate (Product of Regen biopharma)
 - 14.10.1.1 Overview
 - 14.10.1.2 Stage of development
 - 14.10.2 BL-8040 (Drug of Bioline RX)
 - 14.10.2.1 Overview
 - 14.10.2.2 Stage of development
 - 14.10.2.3 Clinical Data

Myelodysplastic syndrome

14.11. Acceleron Pharma

14.12. Celgene Corporation

14.12.1. Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)

14.12.1.1 Overview

14.12.1.2 Stage of development

14.12.1.3 Clinical Data

14.13. Onconova Therapeutics

14.13.1 Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)

14.13.1.1 Overview

14.13.1.2 Stage of development

14.13.1.3 Clinical Data

Iron Deficiency Anemia

14.14. Pieris Pharmaceuticals

14.14.1. PRS-080 (Drug of Pieris Pharmaceuticals)

14.14.1.1 Overview

14.14.1.2 Stage of development

14.14.1.3 Clinical Data

I would like to order

Product name: Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia):
Analysis By Region, By Country (2016-2021) (By Type - Iron Deficiency Anemia, Chronic
Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North
America, Europe, APAC, Latin America, MEA; By Country - USA, Canada, UK, Germany,
India, Brazil, South Africa)

Product link: <https://marketpublishers.com/r/G20D4DD6D6AEN.html>

Price: US\$ 2,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/G20D4DD6D6AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970